You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
紅日藥業(300026.SZ):鹽酸普拉克索片獲得藥品註冊批件
格隆匯 07-20 17:54

格隆匯7月20日丨紅日藥業(300026.SZ)公佈,公司於近日收到國家藥品監督管理局下發的藥品註冊批件(批件號:2021S007732021S00774)。現將相關情況公吿如下:

鹽酸普拉克索片是德國勃林格殷格翰藥業有限公司開發研製的用於治療特發性帕金森病的體徵和症狀,即在整個疾病過程中,包括疾病後期,當左旋多巴的療效逐漸減弱或者出現變化和波動(劑末現象或“開關”波動)時,都可以單獨應用本品(無左旋多巴)或與左旋多巴聯用。

鹽酸普拉克索片目前已被納入國家醫保乙類目錄,據米內網城市和縣級公立醫院抗帕金森氏病化學藥通用名銷售排行顯示,2015-2020年,鹽酸普拉克索制劑均位於榜首。

公司產品鹽酸普拉克索片獲得國家藥品監督管理局的《藥品註冊批件》,標志着公司具備了在國內市場銷售該藥品的資格,進一步豐富了公司的產品線,有助於提升公司產品的市場競爭力,對公司的經營業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account